Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.

One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.

The US biotech major has unveiled plans to open a new research and manufacturing center in the UK, which signals the start of detailed talks with the government about establishing a long-term partnership.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker